Biomarker for detecting thrombus or blood coagulation related diseases and application thereof

Abstract

The invention relates to the technical field of thrombus or blood coagulation related disease detection, in particular to a biomarker and application thereof in thrombus or blood coagulation related disease detection. The marker comprises a blood coagulation factor 13 activating peptide (FXIIIAP) or / and a blood coagulation factor 13 A subunit (FXIIIA). The detection kit provided by the invention comprises a capture antibody and a detection antibody, and is a specific antibody prepared by taking FXIIIAP as an antigen. The biomarker disclosed by the invention has a good application prospect in the aspect of quickly screening and diagnosing thrombus or blood coagulation related diseases including cerebral apoplexy, can greatly improve the sensitivity and specificity of existing diagnosis, speculates the thrombus formation time and degree, and can predict the severity and prognosis of the diseases.

Description

technical field [0001] The invention relates to the technical field of detection of thrombus or coagulation-related diseases, in particular to a biomarker for detecting thrombus or coagulation-related diseases and its application. Background technique [0002] Thrombosis and related coagulation diseases have always been important diagnostic items in clinical diagnosis, involving a wide range of diseases, including cerebral venous thrombosis (CVT), renal vein thrombosis (RVT), venous thrombosis (VTE), myocardial infarction (MI), etc. . Among them, the early diagnosis and early treatment of cerebral venous thrombosis and myocardial infarction are particularly important. Taking cerebral venous thrombosis (an important cause of ischemic stroke) as an example, the existing diagnostic methods mainly include computed tomography (CT) and magnetic resonance imaging (MRI), which are very effective in judging the occurrence, type and severity of stroke. efficient. However, these tec...

AI Technical Summary

Problems solved by technology

Coupled with its shortcomings of low sensitivity and specificity, the application of D-dimer is still controversial

In addition, the test results lack the meaning of treatment guidance, and cannot timely and accurately reflect the coagulation status in the body, and cannot indicate the treatment strategy, such as the effect of anticoagulation, and it is also difficult to confirm whether new thrombus has occurred, because old thrombus can still be dissolved to produce D-dimerization body

Images